The nation of Zimbabwe has declined a significant US health deal valued at 367 million US dollars (£272m) spanning five years over Washington's demand for sensitive biological samples.
This move was revealed following a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson has since clarified that the United States was seeking health data for scientific study and commercial purposes but was not willing to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more negotiations to reach a agreement suitable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Context
This development follows a similar case in neighbouring Kenya, where a high court halted a similar health funding agreement after concerns were raised about the security of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government agreements to boost transparency and responsibility.
As per statements, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration could have provided immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, without any corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Effectively, our country would supply the raw materials for medical research with no certainty that the end products would be available to our citizens should a new disease outbreak arise."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were upending frameworks already set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage potential pandemics.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how future collaboration could be arranged in a manner that respects the independence and dignity of each country."
Health Experts Response
A leading public health body said it recognised the government's concerns, but recommended that talks should continue since a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it added.
This impasse underscores the continuing debate between accepting vital foreign assistance and protecting local interests in an ever more data-driven world.